Rhinal Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-07.
Rhinal Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on August 7, 2025. The filing reports $20K sold. Its industry group is Biotechnology. It names Lawrence Fox (CEO, President and Director), Frank Puglisi (Chief Clinical Officer and Director), Austin Panhans (Chief Financial Officer) (SEC Form D, August 7, 2025).
Is this your company?
Sell to companies like Rhinal Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-07 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Rhinal Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Rhinal Therapeutics Inc., from the filings we hold.
Biotechnology raises by companies based in Nevada, filed within 90 days of this one, largest first.
Get an email when Rhinal Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Rhinal Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Rhinal Therapeutics Inc. →Get the full cited report on Rhinal Therapeutics Inc.
What the filing shows about Rhinal Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rhinal Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Rhinal Therapeutics Inc.'s address as 732 S 6TH St, 4248, Las Vegas, NV 89101.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Rhinal Therapeutics Inc. See pricing
Rhinal Therapeutics Inc. is a registered filer with the SEC (CIK 2080382) and has filed since 2025-08-07. 1 filing is on record, the latest on 2025-08-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Rhinal Therapeutics Inc.'s Form D of 2025-08-07 names Lawrence Fox, Frank Puglisi, Austin Panhans and 2 more as its officers, directors or promoters.
Its new offerings report $20K sold across 1 offering, as its own filings state.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
The First dry powder intranasal GLP-1 treatment platform. With opportunity to address obesity, diabetes, addiction, Alzheimers, and others.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Lawrence Fox is named as Ceo, President and Director on the Form D that Rhinal Therapeutics Inc. filed with the SEC on 7 August 2025, one of 5 people that filing names.
On the filing as: Executive Officer, Director.
Frank Puglisi is named as Chief Clinical Officer and Director on the Form D that Rhinal Therapeutics Inc. filed with the SEC on 7 August 2025, one of 5 people that filing names.
On the filing as: Executive Officer.
Austin Panhans is named as Chief Financial Officer on the Form D that Rhinal Therapeutics Inc. filed with the SEC on 7 August 2025, one of 5 people that filing names.
On the filing as: Executive Officer, Director.
Robert Clayborough is named as Chief Scientific Officer and Director on the Form D that Rhinal Therapeutics Inc. filed with the SEC on 7 August 2025, one of 5 people that filing names.
Mike George is named as Director on the Form D that Rhinal Therapeutics Inc. filed with the SEC on 7 August 2025, one of 5 people that filing names.
5 people named on the filing — 4 holding an executive role and 1 as a director only.
Named as of the 2025-08-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Rhinal Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rhinal Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rhinal Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Rhinal Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Rhinal Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-01 (rhinaltherapeutics.com).
Each opens in a new tab, filled in for Rhinal Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Las Vegas
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/rhinal-therapeutics-inc-form-d-25000001